Your browser doesn't support javascript.
loading
Study of a PST-trained voice-enabled artificial intelligence counselor for adults with emotional distress (SPEAC-2): Design and methods.
Ronneberg, Corina R; Lv, Nan; Ajilore, Olusola A; Kannampallil, Thomas; Smyth, Joshua; Kumar, Vikas; Barve, Amruta; Garcia, Claudia; Dosala, Sushanth; Wittels, Nancy; Xiao, Lan; Aborisade, Gbenga; Zhang, Aifeng; Tang, Zhengxin; Johnson, Jillian; Ma, Jun.
Afiliação
  • Ronneberg CR; Department of Medicine, University of Illinois Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60608, United States of America. Electronic address: corina@uic.edu.
  • Lv N; Department of Medicine, University of Illinois Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60608, United States of America. Electronic address: lvn2017@uic.edu.
  • Ajilore OA; Department of Psychiatry, University of Illinois Chicago, 1601 W. Taylor St., Chicago, IL 60612, United States of America. Electronic address: oajilore@uic.edu.
  • Kannampallil T; Washington University School of Medicine in St. Louis, 660 S. Euclid Ave., St. Louis, MO 63110, United States of America. Electronic address: thomas.k@wustl.edu.
  • Smyth J; Department of Psychology, The Ohio State University, 1835 Neil Ave., Columbus, OH 43210, United States of America. Electronic address: smyth.88@osu.edu.
  • Kumar V; Department of Medicine, University of Illinois Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60608, United States of America. Electronic address: vkumar33@uic.edu.
  • Barve A; Department of Medicine, University of Illinois Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60608, United States of America. Electronic address: amruta@uic.edu.
  • Garcia C; Department of Medicine, University of Illinois Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60608, United States of America. Electronic address: gaclaud2@uic.edu.
  • Dosala S; Department of Medicine, University of Illinois Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60608, United States of America. Electronic address: sdosal3@uic.edu.
  • Wittels N; Department of Medicine, University of Illinois Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60608, United States of America. Electronic address: wittels@uic.edu.
  • Xiao L; Department of Epidemiology and Population Health, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, United States of America. Electronic address: lxiao2@stanford.edu.
  • Aborisade G; Department of Medicine, University of Illinois Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60608, United States of America. Electronic address: gabori2@uic.edu.
  • Zhang A; Department of Psychiatry, University of Illinois Chicago, 1601 W. Taylor St., Chicago, IL 60612, United States of America. Electronic address: aifengz@uic.edu.
  • Tang Z; University of Illinois College of Medicine, 1853 W Polk St, Chicago, IL 60612, United States of America. Electronic address: ztang26@uic.edu.
  • Johnson J; Comprehensive Cancer Center, Atrium Health Wake Forest Baptist, 1 Medical Center Blvd, Winston-Salem, NC 27157, United States of America. Electronic address: jiajohns@wakehealth.edu.
  • Ma J; Department of Medicine, University of Illinois Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60608, United States of America. Electronic address: maj2015@uic.edu.
Contemp Clin Trials ; 142: 107574, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38763307
ABSTRACT

BACKGROUND:

Novel and scalable psychotherapies are urgently needed to address the depression and anxiety epidemic. Leveraging artificial intelligence (AI), a voice-based virtual coach named Lumen was developed to deliver problem solving treatment (PST). The first pilot trial showed promising changes in cognitive control measured by functional neuroimaging and improvements in depression and anxiety symptoms.

METHODS:

To further validate Lumen in a 3-arm randomized clinical trial, 200 participants with mild-to-moderate depression and/or anxiety will be randomly assigned in a 211 ratio to receive Lumen-coached PST, human-coached PST as active treatment comparison, or a waitlist control condition where participants can receive Lumen after the trial period. Participants will be assessed at baseline and 18 weeks. The primary aim is to confirm neural target engagement by testing whether compared with waitlist controls, Lumen participants will show significantly greater improvements from baseline to 18 weeks in the a priori neural target for cognitive control, right dorsal lateral prefrontal cortex engaged by the go/nogo task (primary superiority hypothesis). A secondary hypothesis will test whether compared with human-coached PST participants, Lumen participants will show equivalent improvements (i.e., noninferiority) in the same neural target from baseline to 18 weeks. The second aim is to examine (1) treatment effects on depression and anxiety symptoms, psychosocial functioning, and quality of life outcomes, and (2) relationships of neural target engagement to these patient-reported outcomes.

CONCLUSIONS:

This study offers potential to improve the reach and impact of psychotherapy, mitigating access, cost, and stigma barriers for people with depression and/or anxiety. CLINICALTRIALS gov # NCT05603923.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ansiedade / Inteligência Artificial / Depressão Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ansiedade / Inteligência Artificial / Depressão Idioma: En Ano de publicação: 2024 Tipo de documento: Article